Bavarian Nordic

Bavarian Nordic is providing 75,000 doses of its mpox vaccine MVA‑BN and a further 150,000 doses for a new global emergency stockpile. Stock management will be handled by the International Coordinating Group on Vaccine Provision at the WHO, and the initiative is funded by Gavi. The announcement pushed the share price to a 52‑week high; the company recently raised its full‑year guidance. » More on deraktionaer.de

The Bavarian Nordic share reached a year high of 240 DKK on the Copenhagen exchange after the company raised its forecast. Jefferies still considers the stock undervalued and recommends buy with a 280 DKK target, Van Lanschot Kempen reconfirms a buy with 270 DKK, and SEB names a 300 DKK target. The main driver is stronger sales of rabies vaccines in the US; analysts say the sustainability of this demand is uncertain. The operational performance after the failed takeover in autumn is rated positively and makes the stock attractive for speculative investors. » More on deraktionaer.de

Bavarian Nordic has increased its revenue forecast for the third time this year to around DKK 6.1 billion, driven by stronger travel-vaccine sales, in particular rabies vaccines in the US. The travel-health segment is expected to contribute about DKK 3.4 billion, significantly more than previously anticipated. The company now expects an EBITDA margin of around 32%; the stock then rose intraday by about seven percent to a year high. » More on deraktionaer.de